- WuXi Biologics and HanchorBio signed a strategic collaboration agreement.
- The focus is on developing and manufacturing bi-/multi-functional fusion proteins.
- WuXi Biologics will provide end-to-end biologics development and manufacturing services.
Partnership Announcement
WuXi Biologics, a leading CRDMO, and HanchorBio, a clinical-stage biotechnology company, have announced a strategic collaboration. The agreement focuses on the development and manufacturing of next-generation bi-/multi-functional fusion protein programs from HanchorBio's pipeline.
Scope of Collaboration
Under the agreement, WuXi Biologics will provide comprehensive biologics development and manufacturing services. This includes cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing.
Leadership Involvement
The partnership was formalized by Dr. Chris Chen, CEO of WuXi Biologics, and Dr. Scott Liu, Founder, Chairman, and CEO of HanchorBio. Their leadership underscores the commitment to advancing innovative therapies for oncology and autoimmune diseases.
